Novartis announced that the FDA has approved Menveo (meningococcal [Groups A, C, Y, W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) in infants and toddlers from 2 months of age.

Menveo is a quadrivalent conjugate vaccine indicated to help prevent meningococcal disease caused by four strains of the bacterium Neisseria meningitidis (N. meningitidis).

RELATED: Immunization Resource Center

The FDA approval was based on data from three randomized multicenter studies involving >8,700 infants. The studies showed that Menveo generated a strong immune response and a demonstrated safety profile with concomitant routine pediatric vaccines.

Menveo was approved in February 2010 for use in adolescents and adults 11–55 years old, and was approved in January 2011 for use in children 2–10 years old.

For more information call (877) 683-4732 or visit